Would you pursue adjuvant immunotherapy for a resected stage IIIC or IIID, BRAF wild type, melanoma patient with pre-existing ulcerative colitis that is well managed on maintenance infliximab?  


Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Emory University School of Medicine
I agree with Dr. @Brent A. Hanks. Infliximab can c...
Sign in or Register to read more